Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 610

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 1
Chunk 610
---
 contained in our certificate of incorporation to be inapplicable or unenforceable
in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect
our business and financial condition.

68

Trading in our common stock has
been volatile and may continue to be volatile in the future.

The stock market in general has
experienced extreme price and volume fluctuations. The market prices of the securities of biotechnology and specialty pharmaceutical companies,
particularly companies like ours without product revenues and earnings, have been highly volatile and may continue to be highly volatile
in the future. This volatility has often been unrelated to the operating performance of particular companies.

The following factors, in addition
to other risk factors described in this section, may have a significant impact on the market price of our common stock:

● announcements of technological
innovations or new products by us or our competitors;

● announcement of FDA/CE
approval, disapproval or delay of approval of our product candidates or other product-related actions;

● developments involving
our discovery efforts and clinical trials;

● developments or disputes
concerning patents or proprietary rights, including announcements of infringement, interference or other litigation against us or our
potential licensees;

● developments involving
our efforts to commercialize our products, including developments impacting the timing of commercialization;

● announcements concerning
our competitors, or the biotechnology, pharmaceutical or drug delivery industry in general;

● public concerns as to
the safety or efficacy of our approved product or product candidates or our competitors’ products;

● changes in government
regulation of the pharmaceutical or medical industry;

● changes in the reimbursement
policies of third-party insurance companies or government agencies;

● actual or anticipated
fluctuations in our operating results;

● changes in financial estimates
or recommendations by securities analysts;

● developments involving
corporate collaborators, if any;

● changes in accounting
principles; and

● the loss of any of our
key scientific or management personnel.

In the past, securities class
action litigation has often been brought against companies that experience volatility in the market price of their securities. Whether
or not meritorious, litigation brought against us could result in substantial costs and a diversion of management’s attention and
resources, which could adversely affect our business, operating results and financial condition.

We cannot assure you that our
common stock price and volume will remain at current levels in which case investors may sustain large losses.

In addition, the stock market
in general, and the stocks